Array’s loss widens as biopharma preps for commercialization

BOULDER — Array BioPharma Inc. (Nasdaq: ARRY) on Tuesday reported a loss of $24.2 million, or 17 cents per share, on revenue of $35.4 million for its fiscal second quarter that ended Dec. 31.

Compared with the same quarter of fiscal 2015, the Boulder-based drug development company’s revenue increased $8.5 million, primarily due to $27.3 million in reimbursement revenue from Novartis.  Net loss was roughly triple compared with the $8.6 million, or 6 cents per share, reported for the same quarter in fiscal 2015.

Ron Squarer, Array’s chief executive, said the company continues to make progress with its melanoma-fighting drugs binimetinib and…